BIO Bio-Rad Laboratories Inc

  1. Stocks
  2. Healthcare
  3. NYSE: BIO

Price (delayed)

$319.42

Market cap

$9.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.67

Enterprise value

$10.08B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The company's quick ratio rose by 13% YoY and by 12% QoQ
The net income has shrunk by 69% YoY but it rose by 49% QoQ
The EPS has plunged by 62% YoY but it has soared by 51% from the previous quarter
Bio-Rad Laboratories's gross profit has decreased by 9% YoY and by 2.6% from the previous quarter
The revenue has contracted by 6% YoY and by 2.5% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bio-rad.com/
Peers: TMO BDX HBIO A

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
28.52M
Market cap
$9.11B
Enterprise value
$10.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
3.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
Earnings
Revenue
$2.61B
EBIT
-$394.48M
EBITDA
-$394.48M
Free cash flow
$185.72M
Per share
EPS
-$10.67
Free cash flow per share
$6.51
Book value per share
$317.38
Revenue per share
$91.35
TBVPS
$416.7
Balance sheet
Total assets
$12.61B
Total liabilities
$3.56B
Debt
$1.4B
Equity
$9.05B
Working capital
$2.59B
Liquidity
Debt to equity
0.15
Current ratio
6.57
Quick ratio
4.5
Net debt/EBITDA
-2.45
Margins
EBITDA margin
-15.1%
Gross margin
53.4%
Net margin
-12.4%
Operating margin
12.3%
Efficiency
Return on assets
-2.6%
Return on equity
-3.7%
Return on invested capital
-3.3%
Return on capital employed
-3.2%
Return on sales
-15.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
1.35%
1 week
7.61%
1 month
14.89%
1 year
-24.42%
YTD
-1.07%
QTD
16.96%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.61B
Gross profit
$1.39B
Operating income
$320.59M
Net income
-$322.37M
Gross margin
53.4%
Net margin
-12.4%
The net margin has dropped by 80% year-on-year but it is up by 48% since the previous quarter
The net income has shrunk by 69% YoY but it rose by 49% QoQ
BIO's operating income is down by 19% year-on-year and by 5% since the previous quarter
BIO's operating margin is down by 14% year-on-year and by 2.4% since the previous quarter

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
BIO P/E details
P/E
N/A
P/B
1.01
P/S
3.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.87
The EPS has plunged by 62% YoY but it has soared by 51% from the previous quarter
BIO's P/B is 37% below its 5-year quarterly average of 1.6 and 16% below its last 4 quarters average of 1.2
The equity has contracted by 7% YoY but it has grown by 3.5% from the previous quarter
The stock's price to sales (P/S) is 34% less than its 5-year quarterly average of 5.3 and 8% less than its last 4 quarters average of 3.8
The revenue has contracted by 6% YoY and by 2.5% from the previous quarter

Efficiency

How efficient is Bio-Rad Laboratories business performance
The company's return on invested capital has shrunk by 106% YoY but it has surged by 50% QoQ
The ROS has plunged by 104% YoY but it has increased by 50% from the previous quarter
The ROE has dropped by 76% year-on-year but it is up by 49% since the previous quarter
Bio-Rad Laboratories's ROA has plunged by 73% YoY but it has increased by 49% from the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The company's current ratio rose by 18% YoY and by 13% QoQ
The company's quick ratio rose by 13% YoY and by 12% QoQ
The debt is 85% smaller than the equity
The equity has contracted by 7% YoY but it has grown by 3.5% from the previous quarter
Bio-Rad Laboratories's debt to equity has increased by 7% YoY but it has decreased by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.